NCCN Congress: Hematologic Malignancies | Conferences

Assessing Risk for Optimal Treatment of High-Risk Polycythemia Vera in the Frontline Setting

October 18, 2022

During the NCCN 2022 Annual Congress: Hematologic Malignancies, Aaron Gerds, MD, explained risk stratification in patients with polycythemia vera, frontline treatment options, and outcomes for the patient population based on findings from clinical trials.

Standard of Care in Newly Diagnosed Myeloma

October 19, 2021

Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.

Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need

October 18, 2021

In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.